Company intelligence / Profile preview

NeuroSpa TMS Holdings

Tampa, Florida, United States

Ownership: Private
Employees: ~24
Development stage: Other

Overview

NeuroSpa TMS Holdings operates six Florida clinics offering commercially available, FDA-cleared TMS, Spravato (esketamine), and Ketamine therapies as well as traditional psychiatric services for depression, anxiety, PTSD, and related disorders. Clinics report high response (88%) and remission (60%) rates for TMS in clinical depression, exceeding typical pharmacologic interventions.

Therapeutic areas: Psychiatry
Modalities: DeviceSmall molecule
Industry: Non-Academic Healthcare

Partnerships

Pending: HOPE Therapeutics, Inc. (wholly owned by NRx Pharmaceuticals, Inc. / NASDAQ: NRXP)

Beyond the preview

Go deeper on NeuroSpa TMS Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroSpa TMS Holdings.

Explore the full profile